The clinical development of investigational drugs is a complex and expensive process and recent advances in clinical research, particularly Pharmacogenomics and Personalised Medicine, have increased that complexity and cost.
Regulatory agencies have identified clinical trial simulations as an essential part of drug development. Adoption of simulation has been severely hampered by lack of knowledge of the power of simulations, shortage of expertise, prohibitive costs, long implementation times and access to computing software and power.
In many cases only large companies can access the resources, particularly expertise, in effective simulation. Even then it can take far too long to implement with all the attendant risks of a major long-term project.
Exploristics’ Hot House Study Services enables major, medium sized and small pharmaceutical companies to experience the power and effectiveness of simulation with minimal risk and at the fraction of the cost. With our Hot House simulation studies our experienced staff with many years’ experience of simulations design, implement and run your study through our in-house advanced KerusCloud simulation platform.